Home » EMA May Revise Guidance on Cancer Drug Trials To Harmonize With Recent Appendices
EMA May Revise Guidance on Cancer Drug Trials To Harmonize With Recent Appendices
October 14, 2010
Noting that roughly a third of new chemical and biological entities in clinical development are anti-cancer treatments, the European Medicines Agency (EMA) may update its guideline on trials for anti-cancer drugs.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor